Table S2.
Patient and tumor characteristics
| Clinicopathological parameters | Level | n (%) |
| Age at diagnostis | ≤60 y | 30 (56.6) |
| >60 y | 23 (43.4) | |
| Body mass index | ≤25 y | 31 (58.5) |
| >25 y | 22 (41.5) | |
| HR expression | ER+/PR+ | 31 (59.6) |
| ER+/PR− | 14 (26.9) | |
| ER−/PR− | 7 (13.5) | |
| Missing | 1 | |
| TN | No | 45 (86.5) |
| Yes | 7 (13.5) | |
| Missing | 1 | |
| HER2+ expression | No | 41 (80.4) |
| Yes | 10 (19.6) | |
| Missing | 2 | |
| Tumor stage | 0 | 2 (3.8) |
| I | 17 (32.7) | |
| II | 24 (46.2) | |
| III | 6 (11.5) | |
| IV | 3 (5.8) | |
| Missing | 1 | |
| Pathological nodal stage, pN | pN0 | 26 (49.1) |
| pN+ | 27 (50.9) | |
| Pathological tumor size, pT | ≤2 cm | 22 (44) |
| 2–5 cm | 23 (46) | |
| >5 cm | 5 (10) | |
| Missing | 3 |
HR, Hormone receptor; TN, triple negative (ER−/PR−/HER2−).